小剂量庆大霉素鼓室内注射治疗梅尼埃病对球囊功能的影响
详细信息    查看全文 | 推荐本文 | 收藏本文
  • 作者:张婷 ; 赵铖 ; 杨悦 ; 白艳霞
  • 关键词:梅尼埃病 ; 颈性前庭诱发肌源性电位 ; 庆大霉素 ; 鼓室内注射
  • 中文刊名:中国耳鼻咽喉颅底外科杂志
  • 英文刊名:Chinese Journal of Otorhinolaryngology-Skull Base Surgery
  • 机构:西安交通大学第一附属医院耳鼻咽喉头颈外科;
  • 出版日期:2020-04-30
  • 年:2020
  • 期:02
  • 基金:陕西省自然科学基金(2019JQ-247);; 西安交通大学第一附属医院院基金(2016QN-24)
  • 页:61-64
  • CN:43-1241/R
  • ISSN:1007-1520
  • 分类号:R764.33
摘要
目的应用颈性前庭诱发肌源性电位(cVEMP)研究小剂量庆大霉素鼓室内注射对球囊功能的影响,以指导临床用药。方法回顾性分析2016年5月—2018年10月行耳内镜下鼓室内注射庆大霉素(30 mg/mL)治疗的26例单侧梅尼埃病患者,于注射前及注射后3周分别行纯音听阈测试(PTA)及cVEMP检查,比较注射前后患者听力及cVEMP结果。结果 26例梅尼埃病患者随访12~24个月,眩晕控制率为92.31%(24/26)。注射前患耳平均气导听阈为(61.80±2.79)dBHL,注射后为(64.40±2.51)dBHL,注射前后听力差异无统计学意义(P>0.05)。cVEMP检查提示注射前4例(15.38%)未引出,22例注射前患侧P1平均潜伏期为(16.51±2.46)ms,N1平均潜伏期为(27.57±3.36)ms;注射后12例(46.15%)未引出,其他14例P1平均潜伏期为(18.88±1.84)ms,N1潜伏期(30.57±1.45)ms。可见注射后引出率下降,P1、N1潜伏期延长。注射前后患侧P1、N1潜伏期的结果差异具有统计学意义(P<0.05)。结论鼓室内注射小剂量庆大霉素可抑制或破坏球囊功能,cVEMP检查有助于评价此治疗的有效性及安全性。
    
引文
[1] Lopez-Escamez JA,Carey J,Chung WH,et al.Diagnostic criteria for Meniere’s disease[J].J Vestib Res,2015,25(1):1-7.
    [2] Foster CA,Breeze RE.Endolymphatic hydrops in Meniere’s disease:cause,consequence,or epiphenomenon [J].Otol Neurotol,2013,34(7):1210-1214.
    [3] Zhai F,Zhang R,Zhang T,et al.Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable Meniere’s disease [J].Audiol Neurootol,2013,18(5):297-306.
    [4] 中华耳鼻咽喉头颈外科杂志编辑委员会,中华医学会耳鼻咽喉头颈外科学分会.梅尼埃病诊断和治疗指南(2017)[J].中华耳鼻咽喉头颈外科杂志,2017,52(3):167-172.
    [5] Wu Q,Dai C,Zhao M,et al.The correlation between symptoms of definite Meniere’s disease and endolymphatic hydrops visualized by magnetic resonance imaging[J].Laryngoscope,2016,126(4):974-979.
    [6] Young YH,Huang TW,Cheng PW.Assessing the stage of Meniere’s disease using vestibulare evoked myigenic potentials[J].Arch Otolaryngol Head Neck Surg,2003,129(8):815-818.
    [7] Colebatch JG,Halmagyi GM.Vestibular evoked potentials in human neck muscles before and after unilateral vestibular deafferentation[J].Neurology,1992,42(8):1635-1636.
    [8] Taylor RL,Wijewardene AA,Gibson WP,et al.The vestibular evoked-potential profile of Meniere’s disease[J].Clin Neurophysiol,2011,122(6):1256-1263.
    [9] 刘维,汪芹,伍伟景.内耳钆造影MRI技术的原理及临床应用进展[J].中国耳鼻咽喉颅底外科杂志,2019,25(4):439-443.
    [10] 李斐,庄建华,陈瑛,等.梅尼埃病不同听力分期中颈肌前庭诱发肌源性电位的差异[J].临床耳鼻咽喉头颈外科杂志,2016,30(1):9-12.
    [11] van Tilburg MJ,Herrmann BS,Guinan JJ Jr,et al.Serial cVEMP testing is sensitive to disease progression in Ménière patients[J].Otol Neurotol,2016,37(10):1614-1619.
    [12] Zhai F,Liu JP,Dai CF,et al.Evidence-based modification of intratympanic gentamicin injections in patients with intractable vertigo[J].Otol Neurotol,2010,31(4):642-648.
    [13] Zhang R,Zhang YB,Dai CF,et al.Temporal and spatial distribution of gentamicin in the peripheral vestibular system after transtympanic administration in guinea pigs[J].Hear Res,2013,298:49-59.
    [14] Helling K,Sch?nfeld U,Clarke AH.Treatment of Meniere’s disease by low-dosage intratympanic gentamicin application:effect on otolith function[J].Laryngoscope,2007,117(12):2244-2250.
    [15] Marques P,Manrique-Huarte R,Perez-Fernandez N.Single intratympanic gentamicin injection in Meniere’s disease:VOR change and prognostic usefulness[J].Laryngoscope,2015,125(8):1915-1920.
    [16] Bertino G,Durso D,Manfrin M,et al.Intratympanic gentamicin in monolateral Meniere’s disease:our experience[J].Eur Arch Otorhinolaryngol,2006,263(3):271-275.
    [17] Uchino Y,Kushiro K.Differences between otolith and semicircular canal-activated neural circuitry in the vestibular system[J].Neurosci Res,2011,71(4):315-327.

中国园林博物馆北京筹备办公室 | 版权所有,未经许可严禁复制或镜像

地址:北京市丰台区射击场路15号 邮编:100072 

京ICP备19031310号     京公网安备11010602006846号